Milestone Pharmaceuticals Inc.
NASDAQ Global SelectTotal Valuation
Milestone Pharmaceuticals Inc. carries a market capitalization of 109.94M, placing it among publicly traded companies globally. Its enterprise value stands at -8.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 109.94M |
| Enterprise Value | -8.71M |
Share Statistics
Milestone Pharmaceuticals Inc. currently has 117.79M shares outstanding.
| Shares Outstanding | 117.79M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 65.18, and the price-to-book ratio stands at -1.40.
| PE Ratio | N/A |
| PS Ratio | 65.18 |
| PB Ratio | -1.40 |
| P/TBV Ratio | 3.23 |
| P/FCF Ratio | -2.29 |
| P/OCF Ratio | -2.27 |
Enterprise Valuation
| EV / Sales | 16.84 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Milestone Pharmaceuticals Inc. maintains a current ratio of 9.18, meaning it holds 9.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 164.27, indicating elevated leverage, while an interest coverage ratio of -9.26 demonstrates limited ability to service its debt obligations.
| Current Ratio | 9.18 |
| Quick Ratio | 9.03 |
| Debt / Equity | 164.27 |
| Debt / EBITDA | -0.91 |
| Interest Coverage | -9.26 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -53.49 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.02 |
Stock Price Statistics
Milestone Pharmaceuticals Inc.'s stock has declined approximately -22.42424% over the past 52 weeks. The 50-day moving average sits at 1.66, while the 200-day moving average is 1.89.
| Beta (5Y) | N/A |
| 52-Week Price Change | -22.42424% |
| 50-Day Moving Average | 1.66 |
| 200-Day Moving Average | 1.89 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Milestone Pharmaceuticals Inc. generated 1.78M in revenue and converted that into -68.36M in net income, yielding earnings per share of -0.70. EBITDA reached -65.14M, while operating income came in at -65.28M.
| Revenue | 1.78M |
| Gross Profit | 224,000.00 |
| Operating Income | -65.28M |
| Pretax Income | -68.36M |
| Net Income | -68.36M |
| EBITDA | -65.14M |
| EBIT | -65.28M |
| Earnings Per Share (EPS) | -0.70 |
Balance Sheet
Milestone Pharmaceuticals Inc. holds 184.22M in cash and equivalents against 59.22M in total debt, resulting in a net debt position of -13.12M. Total book value stands at -82.97M, with working capital of 171.31M providing operational flexibility.
| Cash & Cash Equivalents | 184.22M |
| Total Debt | 59.22M |
| Net Debt | -13.12M |
| Equity (Book Value) | -82.97M |
| Book Value Per Share | -0.85 |
| Working Capital | 171.31M |
Cash Flow
Milestone Pharmaceuticals Inc. produced -51.14M in operating cash flow over the past twelve months. After subtracting -341,000.00 in capital expenditures, free cash flow totaled -51.48M - equivalent to -0.53 per share.
| Operating Cash Flow | -51.14M |
| Capital Expenditures | -341,000.00 |
| Free Cash Flow | -51.48M |
| FCF Per Share | -0.53 |
Margins
Milestone Pharmaceuticals Inc. operates with a gross margin of 99.22, reflecting its pricing power and cost economics. The operating margin of -3,659.19 and net profit margin of -3,832.01 provide insight into operational efficiency.
| Gross Margin | 99.22 |
| Operating Margin | -3,659.19 |
| Pretax Margin | -3,832.01 |
| Profit Margin | -3,832.01 |
| EBITDA Margin | -3,651.18 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -154.57 |
| FCF Yield | -43.69 |
Scores
Milestone Pharmaceuticals Inc. posts an Altman Z-Score of -2.90, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.90 |